Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABCHIX:QLINES 67 3-Year EBITDA Growth Rate is 72.30% as of Jun. 2026, which is 2091% above its 10-year median of 3.30. GuruFocus rates CHIX:QLINES with a GF Score™ of 67/100 and a GF Value™ of kr1,914.44. The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Q-linea AB ranks better than 94.51% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 72.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 50.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Q-linea AB was 72.30% per year. The lowest was -44.30% per year. And the median was 3.30% per year.
Q-linea AB (CHIX:QLINEs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Q-linea AB 3-Year EBITDA Growth Rate Related Terms
CHIX:QLINES vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Q-linea AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Q-linea AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 72.30% mean?
Q-linea AB (CHIX:QLINES) has a 3-Year EBITDA Growth Rate of 72.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Q-linea AB and its competitors. This is 2091% above median its historical median of 3.30. According to the industry distribution chart, Q-linea AB ranks #38 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 5.5%.
Is Q-linea AB's 3-Year EBITDA Growth Rate too high?
Q-linea AB's current 3-Year EBITDA Growth Rate of 72.30% is 2091% above median its 10-year median of 3.30. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Q-linea AB's value of 72.30% is 781.7% above this industry median. Based on the distribution chart, Q-linea AB ranks #38 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #38 out of 692 companies for 3-Year EBITDA Growth Rate. This places Q-linea AB in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Q-linea AB's value of 72.30% is 781.7% above this benchmark. While the company's 10-year median is 3.30 vs. the industry median of 8.20, Q-linea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current 3-Year EBITDA Growth Rate of 72.30% is 781.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current 3-Year EBITDA Growth Rate is 72.30%, which is 2091% above median its own 10-year median of 3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current 3-Year EBITDA Growth Rate of 72.30%. The stock's GF Value™ is kr1,914.44, compared to a current price of kr1,610.00 — trading 15.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 72.30%, which is 2091% above median its 10-year median of 3.30 and 781.7% above the Medical Devices & Instruments industry median of 8.20. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current 3-Year EBITDA Growth Rate is 72.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 15.9% below its estimated GF Value™ of kr1,914.44.
Key valuation signals for CHIX:QLINES:
3-Year EBITDA Growth Rate: 72.30% (2091% above median its 10-year median of 3.30)
GF Value™: kr1,914.44 vs. price of kr1,610.00 (15.9% below fair value)
Industry Position: 781.7% above the Medical Devices & Instruments median (#38 of 692)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score
Get the complete analysis for CHIX:QLINES
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
